Effects of Abiraterone Acetate on Chronic Kidney Disease in 2 Patients With Metastatic Castration-resistant Prostate Cancer

被引：4

作者：

Francini, Edoardo ^{[1
]}

Petrioli, Roberto ^{[3
]}

Fiaschi, Anna Ida ^{[2
]}

Laera, Letizia ^{[3
]}

Roviello, Giandomenico ^{[3
]}

机构：

[1] Univ Rome, Policlin Umberto Hosp 1, Med Oncol Unit, Rome, Italy

[2] Univ Siena, Pharmacol Unit, I-53100 Siena, Italy

[3] Univ Siena, Med Oncol Unit, I-53100 Siena, Italy

来源：

MEDICINE | 2014年 / 93卷 / 27期

关键词：

INCREASED SURVIVAL; IMMUNOTHERAPY; MITOXANTRONE; PREDNISONE; CYP17;

D O I：

10.1097/MD.0000000000000163

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Prostate cancer is the second leading cause of cancer-related death in men in most Western countries. In this report, we present 2 cases of metastatic castration-resistant prostate cancer and chronic kidney disease. Both patients underwent and developed clinical resistance to androgen-deprivation therapy. Subsequently, the patients were treated with the conventional chemotherapeutic approach, which resulted in the worsening of renal function and performance status. Therefore, we opted for treatment with abiraterone acetate, and the patients exhibited improvements in renal function with good response of the disease.

引用

页数：3

共 50 条

[21] Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide [J].

Noonan, K. L. ;

North, S. ;

Bitting, R. L. ;

Armstrong, A. J. ;

Ellard, S. L. ;

Chi, K. N. .

ANNALS OF ONCOLOGY, 2013, 24 (07) :1802-1807

[22] A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer [J].

McKay, Rana R. ;

Werner, Lillian ;

Jacobus, Susanna J. ;

Jones, Xandra ;

Mostaghel, Elahe A. ;

Marck, Brett T. ;

Choudhury, Atish D. ;

Pomerantz, Mark M. ;

Sweeney, Christopher J. ;

Slovin, Susan F. ;

Morris, Michael J. ;

Kantoff, Philip W. ;

Taplin, Mary-Ellen .

CANCER, 2019, 125 (04) :524-532

[23] Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors [J].

Procopio, Giuseppe ;

Grassi, Paolo ;

Testa, Isabella ;

Verzoni, Elena ;

Torri, Valter ;

Salvioni, Roberto ;

Valdagni, Riccardo ;

de Braud, Filippo .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (05) :479-482

[24] Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate [J].

Fiala, Ondrej ;

Hosek, Petr ;

Korunkova, Hana ;

Hora, Milan ;

Kolar, Jiri ;

Sorejs, Ondrej ;

Topolcan, Ondrej ;

Filipovsky, Jan ;

Liska, Vaclav ;

Santoni, Matteo ;

Buti, Sebastiano ;

Finek, Jindrich .

CANCER MEDICINE, 2024, 13 (01)

[25] Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors [J].

Romero, Miguel E. jimenez ;

Gallego, Maria Camacho ;

Serrato, Jose c. navarro ;

Sanchez Hurtado, Miguel A. ;

Santotoribio, Jose D. .

ANTICANCER RESEARCH, 2021, 41 (08) :3955-3968

[26] Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer [J].

Mckay, R. R. ;

Werner, L. ;

Fiorillo, M. ;

Nakabayashi, M. ;

Kantoff, P. W. ;

Taplin, M-E .

PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (04) :398-405

[27] Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer [J].

Chi, K. N. ;

Tolcher, A. ;

Lee, P. ;

Rosen, P. J. ;

Kollmannsberger, C. K. ;

Papadopoulos, K. P. ;

Patnaik, A. ;

Molina, A. ;

Jiao, J. ;

Pankras, C. ;

Kaiser, B. ;

Bernard, A. ;

Tran, N. ;

Acharya, M. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) :237-244

[28] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer [J].

Schmid, Sebastian Christoph ;

Geith, Alexander ;

Boeker, Alena ;

Tauber, Robert ;

Seitz, Anna Katharina ;

Kuczyk, Markus ;

von Klot, Christoph ;

Gschwend, Juergen Erich ;

Merseburger, Axel Stuart ;

Retz, Margitta .

ADVANCES IN THERAPY, 2014, 31 (02) :234-241

[29] A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer [J].

Ueda, Yujiro ;

Matsubara, Nobuaki ;

Takizawa, Itsuhiro ;

Nishiyama, Tsutomu ;

Tabata, Ken-ichi ;

Satoh, Takefumi ;

Kamiya, Naoto ;

Suzuki, Hiroyoshi ;

Kawahara, Takashi ;

Uemura, Hiroji .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (08) :774-779

[30] Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate [J].

Miyoshi, Yasuhide ;

Uemura, Koichi ;

Kawahara, Takashi ;

Yoneyama, Shuko ;

Hattori, Yusuke ;

Teranishi, Jun-ichi ;

Ohta, Jun-ichi ;

Takebayashi, Shigeo ;

Yokomizo, Yumiko ;

Hayashi, Narihiko ;

Yao, Masahiro ;

Uemura, Hiroji .

CLINICAL GENITOURINARY CANCER, 2017, 15 (04) :472-478

← 1 2 3 4 5 →